CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 5,655 shares, a decrease of 81.2% from the July 15th total of 30,057 shares. Based on an average trading volume of 329,145 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, CytoMed Therapeutics presently has an average rating of “Sell”.

Get Our Latest Research Report on GDTC

Shares of GDTC opened at $0.84 on Wednesday. CytoMed Therapeutics has a one year low of $0.68 and a one year high of $3.68. The company has a 50-day moving average of $1.00 and a two-hundred day moving average of $1.01. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.06.

(Get Free Report)

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.

• Five stocks we like better than CytoMed Therapeutics
• Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
• AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
• NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
• Apple’s Next iPhone Could Test How Much Pricing Power Is Left

Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Wasatch Advisors LP Purchases 10,749 Shares of Champion Homes, Inc. $SKY

Invesco S&P SmallCap Industrials ETF (NASDAQ:PSCI) Short Interest Update